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Abstract: In cervical cancer, glycosylation has been suggested as being involved in both its carcinogenesis and
invasive capacity. In this work, we analyzed mucin type O-glycosylation in biopsies of invasive cervical cancer in
FIGO stage II B through histochemistry using lectins specific for O-glycosidically linked glycans. Our results
reveal that the lectin Machaerocereus eruca (MeA, specific for Gal in a Fuca1,2 (GalNAca1,3) Galb1,4) showed
increased recognition of tumoral cells and tumoral stroma tissue compared to other lectins with similar specific-
ity; healthy cervical tissue was negative for MeA. Trypsin treatment of recognized tissues abolished MeA’s rec-
ognition; moreover, interaction of MeA was inhibited with oligosaccharides from mucin. As demonstrated by
Western blot of 2-D electrophoresis, MeA recognized ten glycoproteins in the range from 122 to 42 kDa in
cervical cancer lysates. The LC-ESI-MS/MS analysis of the MeAs’ recognized peptides revealed that the latter
matched mainly with the amino acid sequences of lamin A/C, vimentin, elongation factor 2, keratin 1, and beta
actin. Our results suggest that MeA recognizes a complex of over-expressed O-glycosidically-linked proteins that
play a relevant role in cervical cancer’s invasive capacity. O-glycosylation participates in the disassembly of inter-
cellular junctions favoring cancer progression. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 3, 398–406)
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Introduction
Invasive cervical cancer constitutes 9.8% of cancers
worldwide; it is also the commonest epidermoid can-
cer with a high mortality rate. The invasive capacity
of cervical cancer is the most relevant feature of this
cancer type. There is increasing evidence that glyco-
sylation of proteins and glycolipids located on the
cellular surface or in the extracellular matrix play an
important role in cellular recognition and in the or-
ganization of tissues and organs [1]. Moreover, altered
carbohydrates expression is closely related to certain
diseases and to the progression of neoplasms [2], such
as in the human urinary tract [3], digestive tract [4],
lung [5], and  genital organs [6, 7], among others. The
specific role of tumor-associated glycoconjugates in
diverse cell interactions is not clear; in some neo-
plasms, there are frequent alterations of cellular sur-
face glycoconjugates due to incomplete synthesis, with
or without accumulation of precursors, synthesis of
neo-glycoconjugates, or structural reorganization/re-
distribution of glycoconjugates in cellular membranes
[1, 8, 9]. It has been suggested that cell surface glyco-
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conjugates seem to be pivotal for oncogenic transfor-
mation, facilitating tumor cell migration and metasta-
sis by affecting cell-cell and cell-matrix interactions
[2, 10, 11].
The participation of O-glycosidically-linked gly-
cans (based on a Galb1,3GalNAcaSer/Thr or Gal-
NAcaSer/Thr-containing core) in tumor cells adhe-
sion and metastasis has been proposed based on the
existence of O-glycans-mediated adhesion moieties
in highly metastatic murine cells [12]. Lectins, due to
their capacity to recognize carbohydrates, have been
considered important tools for oligosaccharide char-
acterization, as well as for isolation of cellular popu-
lations [13]. The active participation of O-glycosid-
ically linked glycans in cervical dysplasia has been
strongly suggested by the fact that lectins showing
relatively similar sugar specificity for Gal or GalNAc,
such as those from Amaranthus leucocarpus, Arachis
hypogaea (PNA), or Dolichus biflorus (DBA), have
shown differential staining of tissues according to
cervical dysplasia progression [14, 15]. The aim of this
study was to identify the expression of mucin-type
structures in invasive cervical cancer using lectins with
well-known sugar specificity to elucidate the possible
participation of O-glycosylated structures in cancer
progression.
Material and methods
Tissues. Biopsies derived from patients with epidermoid
cervical cancer (n = 5) were classified as FIGO IIB accord-
ing to the International Federation of Gynecology and Ob-
stetrics system, and as T2b, N0, M0, according to the Amer-
ican Joint Committee on Cancer system. Normal cervical
tissues (n = 5) were derived from hysterectomies carried
out for non-oncological reasons (used for comparison pur-
poses) and obtained from the Departamento de Medicina
Genomica, Hospital General de México, Secretaría de Sa-
lud, Mexico City, Mexico. The Ethics Surveillance Commit-
tee of the hospital authorized the use of tissue in this evalu-
ated research protocol. All samples were obtained after in-
formed consent from patients, and tissues were fixed in 4%
phosphate-buffered paraformaldehyde and embedded in
paraffin. The tissue specimens were diagnosed using stan-
dard histopathological criteria by experienced pathologists.
Lectins. The Amaranthus leucocarpus lectin (ALL; specific
for GalNAc in Galb1,3-GalNAc-a1,0-Ser/Thr) was purified
by affinity chromatography [16]. Machaerocereus eruca ag-
glutinin (isoform MeA-II; specific for OH- in C4 from Gal
in the Fuca 1,2 (GalNAca1,3) Galb1,4 sequence from com-
plex mucin structures) was purified from cactus stems by
affinity chromatography on mucin-Sepharose 4B [17]. Ara-
chis hypogaea agglutinin (PNA; specific for Gal in
Galb1,3GalNAc or Galb1,4GlcNAc sequences in glycopro-
teins or glycolipids) was purchased from EY Lab (San Ma-
teo, CA, USA). Lectins were labeled with the N-hydrox-
ysuccinimide ester of biotin from Pierce Chem. Co. (Rock-
ford, IL, USA) at a label/protein ratio of 2:1 [18]. Oligosac-
charides (containing Gal2 GlcNAc3Fuc1GalNac1GalNAc-
ol) used for inhibition assays with MeA were purified from
porcine stomach mucin after alkaline reductive treatment
and FPLC purification as described in [19].
Hematoxylin and eosin stain (H&E). The tissues stained
with hematoxylin-eosin were observed through a Leica DM/
/LS microscope at 40 ×, and photographed using images
captured with a digital Leica DFC-300FX camera (Leica
Microsystems Digital Imaging, Cambridge, UK) and pro-
cessed with Leica Software IM1000 (Imagic Bildverarbei-
tung AG, Leica Microsystems, Heerbrugg, Switzerland).
Histochemistry. Sections (5-μm thick) were deparaffinized
and re-hydrated according to conventional histological tech-
niques. Then they were rinsed with a phosphate-buffered
saline (PBS, 50 mM sodium phosphate, 0.15 M NaCl, pH
7.4). Unspecific binding sites were blocked by IgG-free 2%
bovine serum albumin (BSA, Sigma, St Louis, MO, USA),
for 30 min. Afterwards, specimens were incubated for
10 min with 0.2% Triton X-100 in PBS, rinsed with 1 mM
PBS-Ca2+, and, then, tissue sections were incubated with bi-
otinylated lectins (MeA and PNA, 1:100; ALL 1:200, as opti-
mal dilutions) at 37°C in a humid-storage chamber for 2 h.
Slides were rinsed twice with PBS-Ca2+ and incubated at 37°C
with extravidin-fluorescein isothiocyanate (FITC; Sigma), di-
lution 1:60, in a dark humid-storage chamber for 1 h, the
slides were sealed with a DAPI-containing VectaShield
mounting medium (Vector Labs, Burlingame, CA, USA) [20].
Trypsin treatment of tissues. Slides were deparaffinized and
re-hydrated similarly as described for histochemistry and
rinsed with PBS.  Tissues were incubated with 2% trypsin
(Gibco, Grand Island, NY, USA) in PBS at several time
intervals (30 to 120 min) at 37°C in a humidified chamber.
Then, tissues were washed with PBS and incubated for
30 min with IgG-free 2% BSA and washed for 10 min with
0.2% Triton X-100. Exhaustive rinses with PBS-CaCl2 were
made before the specimens were incubated for 2 h with bi-
otinylated lectins, as indicated.
Fluorescence microscopy. Slides were observed through
a Leica DM/LS fluorescent microscope (Leica Microsys-
tems, Wetzlar, Germany) with 10 ×, 20 ×, 40 ×, 63 ×, and
100 × objectives. Fluorochromes were visualized with their
specific filters and analyzed in two channels: green for lec-
tins and blue for nuclei. Images were captured with a Leica
DFC-300FX digital camera (Leica) adapted to the micro-
scope. The images were projected with a Leica IM1000 ver-
sion 1.20 release-9 computer-based program (Leica Micro-
systems Digital Imaging, Cambridge, UK).
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Specificity of lectin labeling. To determine the specificity in
the interaction of lectins with tissues, control assays were
performed using lectins incubated previously with 100 mM
GalNAc and lactose, for ALL and PNA lectins, respective-
ly, or 10 μM oligosaccharides from porcine stomach mucin
for MeA [19], prior to labeling the tissues.
Two-dimensional (2-D) polyacrylamide gel electrophoresis.
Before electrophoresis, the cervical cancer tissues were ly-
sed in a solution of PBS containing 1 μg/ml aprotinin-A,
1 μg/ml pepstatin, 2 μg/ml leupeptin, 2 mM phenylmethyl-
sulfonyl fluoride, and 1.0% (v/v) Triton X-100 (lysis buffer),
for 30 min at 4°C, under shaking. Nuclei, cell debris, and
mitochondria were removed by centrifugation, first for 10
min at 250 × g and then for 30 min at 18,000 × g; the clear
supernatant was used for 2-D electrophoresis assays. Iso-
electric focusing was carried out as follows: the lysed tissues
(90 μg of total protein) were treated with a 2D-Clean-Up
kit (Amersham Biosciences). The protein pellet was resus-
pended and the final volume was adjusted to 125 μl with
rehydration buffer (8 M urea, 2% CHAPS, 0.5% of IPG
buffer, pH 4–7, and 20 mM DTT). The sample was used to
rehydrate 7-cm immobilized, pH 4–7, linear gradient strips
(Immobiline DryStrips, GE Healthcare) for 16 h at room
temperature (RT), following the manufacturer’s instruc-
tions. Focusing started at 300 V (1 h), increased to 1,000 V
(0.5 h), and further increased to 5,000 V (2 h) in an Ettan
IPGphor III Electrophoresis Unit (GE Healthcare). After
focusing, the strips were equilibrated for 20 min in equilib-
rium buffer (2% SDS, 50 mM Tris-HCl, pH 8.8, 6 M urea,
30% glycerol, 0.002% bromophenol blue, and 0.5% DTT).
The strips were then overlaid on 12% SDS polyacrylamide
gels and, after electrophoresis, proteins were transferred to
Immobilon-P PVDF membranes (Millipore Corp, Billerica,
MA, USA). Membranes were stained with Coomassie Bril-
liant Blue R-250 and used to perform lectin-blotting assays.
MeA-blotting assays. Proteins from the 2-D SDS-PAGE
were transferred to PVDF membranes and incubated with
1 μg/ml of MeA-HRP in PBS containing 0.05% Tween 20
and 3% BSA (PBS-TB) in the presence or absence of 100
μg stomach mucine oligosaccharides for 1 h at room tem-
perature (22 ± 2°C), according to the method described by
Towbin et al. [21]. After incubation, membranes were rinsed
with PBS containing 0.05% Tween 20 (PBS-T) and MeA
reactivity was revealed with 3 mg/ml of 3,3-diaminobenzi-
dine in PBS-T and 30% hydrogen peroxide diluted 1:1,000.
Analytical methods. Protein concentration was determined
according to the Lowry procedure modified by Peterson,
using bovine serum albumin as standard [22].
Nano LC-ESI-MS/MS. Protein spots from the lysed tissues
and recognized by the lectin MeA after 2-D electrophore-
sis were excised from the SDS-PAGE with a sterile scalpel.
The gel pieces were washed with 50% (v/v) acetonitrile in
25 mM ammonium bicarbonate (pH 8.5) for 15 min twice
to remove Coomassie dye. After dehydration with 100%
(v/v) acetonitrile for 10 min at room temperature, the gel pieces
were vacuum-dried and rehydrated with sequencing-grade
modified trypsin (Promega, Madison, WI, USA) in 25 mM
ammonium bicarbonate (pH 8.5) at 37°C overnight. The
in-gel tryptic digested samples were injected into an inte-
grated nano-LC-ESI-MS/MS system (quadrupole/time of
flight, Ultima API, Micromass, Manchester, UK). The in-
jected samples were first trapped and desalted isocratically
on an LC-Packing PepMap C18 μ-pre-column cartridge (Di-
onex, Sunnyvale, CA, USA). After dissolving with 0.1% for-
mic acid, the samples were loaded into an analytical C18
capillary column connected online to the mass spectrome-
ter. Instrumental operation, data acquisition, and analysis
were performed under the full control of Mass-Lynx 4.0
(Micromass). The 1-s survey scans were run over the mass
range of m/z 400 to 2000. The acquired peptide ions were
analyzed with the Mascot program (www.matrixscience.com)
using both NCBInr and EST databases. Parameters for the
Mascot search were peptide mass tolerance of 1 Da;
MS/MS ion mass tolerance of 1 Da, maximally one missed
cleavage, and tryptic digestion. Variable modifications in-
cluded methionine oxidation and cysteine carbamidometh-
ylation. Only proteins with significant ion scores (> 62) were
reported [23].
Results
Analysis by light microscopy of cervical tissues
In cervical tissues from healthy individuals, non-kera-
tinized stratified epithelium, in proliferative phase,
without alterations was identified in either epthelia
or stroma (Figure 1A). All analyzed cervico-uterine
cancer tissues depicted a loss of epithelial border with-
in the stroma, many pleomorphic cells showing big
nuclei, as well as loss of the nuclei/cytoplasm relation
and infiltration of the stroma. In addition, inflamma-
tory infiltrate with predominantly mononuclear and
lymphocytic cells in the stromal region was observed
(Figure 1E).
Histochemistry with lectins
In healthy tissues, the lectin PNA showed the capac-
ity to recognize, with low intensity, the plasmatic
membrane of epithelial cells from the superficial stra-
tus. This lectin was not able to recognize epithelial
cells of the basal or intermedial stratus, nor the cellu-
lar components of the extracellular matrix in the cer-
vical stroma (Figure 1B). PNA in cervico-uterine can-
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cer tissue showed moderate reactivity to the plasmat-
ic membrane from neoplasic cells that infiltrated the
stroma; this lectin recognized some endothelial cells
of blood vessels and, with moderate intensity, some
components of the extracellular matrix from the tu-
moral stroma (Figure 1F).
In healthy tissues, the lectin ALL recognized with
low or moderate capacity the plasmatic membrane of
epithelial cells from the superficial stratus; this lectin
did not recognize epithelial cells from the basal or
intermediate stratus. No other components from the
cellular or the extracellular cervical stroma were
identified by this lectin (Figure 1C). As shown in Fig-
ure 1G, in cervico-uterine cancer tissue, the lectin
ALL showed low to intense reactivity toward the plas-
matic membrane of tumoral cells; moreover, this lec-
tin showed moderate reactivity toward the extracel-
lular matrix and also to the vascular endothelium and
adventitia of blood vessels.
In the cervix from healthy individuals, the lectin
from the cactus, MeA, showed no reactivity toward
any epithelial structure, cellular component, nor to
the cervical stromal matrix (Figure 1D); whereas, as
shown in Figure 1H, this lectin showed intense posi-
tive reaction toward cells and stroma (Table 1), as well
as low to moderate reactivity toward blood vessels
endothelium in cervical tissues from cancer patients.
Specificity of lectin labeling
To determine the specificity in the interaction of lec-
tins with tissues, control assays were performed us-
ing lectins incubated for 30 min with 100 mM lactose
for PNA or 100 mM GalNAc for ALL to inhibit their
interaction (not shown). Incubation of MeA with
10 μM porcine stomach mucin oligosaccharides pri-
or to adding the corresponding lectin to the tissues,
completely inhibited MeA staining (Figure 2C);
whereas Gal inhibited partially the interaction of MeA
(Figure 2D). Other monosaccharides, such as 100 mM
Glc, Man, L-Fuc, GalNAc, and GlcNAc, failed to in-
hibit the positive labeling of the MeA lectin.
Trypsin treatment of tissues
Tissues from normal cervix and from cervico-uterine
cancer were treated with trypsin at different time in-
tervals. Control assays showed that the treatment with
trypsin increased reactivity to PNA in all healthy and
cancer tissues with an optimal 120-min treatment time
(not shown). Healthy tissues remained negative for
MeA after trypsin treatment (not shown). However,
reactivity to MeA (Figure 3B) by cancer tissues di-
minished after 30 min of treatment with this protease
(Figure3C), compared to non-treated MeA positive
tissues (Figure 3B); interestingly, after 120 min of
trypsin treatment, reactivity to MeA was abolished
(Figure 3D).
Immunoblotting with M. eruca agglutinin
and Nano LC-ESI-MS/MS analysis
The 2-D electrophoresis of cervical cancer tissues
revealed several spots within the range of 180–15 kDa.
Cervical cancer tissues resolved by 2-D electrophore-
sis were evaluated for MeA binding (Figure 4A).
Three different experiments were performed, and
reactive MeA spots were considered positive only if
they were represented in the three assays. As demon-
strated by Western blot of 2-D electrophoresis from
the cancer cervical lysate, MeA recognized a com-
plex of ten glycoproteins in the range of 126 to
42 kDa (Figure 4B). Control assays using MeA, pre-
viously incubated with 100 μM of mucin oligosaccha-
rides, showed no recognition of transferred glycopro-
teins (not shown). Nano LC-ESI-MS/MS analysis
identified that six of the recognized glycoproteins
showed significant ion scores (> 62) corresponding to
lamin A/C, vimentin, elongation factor 2, keratin 1, and
the 42-kDa beta actin (Table 2).
Discussion
Mucin type O-glycosylation is a postranslational mod-
ification of proteins and lipids performed in the Gol-
gi apparatus [1, 2]. Alterations in O-glycosylation of
proteins in cell surfaces can originate in disorders
of cellular function, as well as in cell transformation
and tumoral differentiation. Subtle modifications in
the mucin-type O-glycosylation pattern could be con-
sidered for the diagnosis or prognosis of cervical pre-
cancerous stages [24]. O-glycosylation in cervical in-
traepithelial dysplasia (CIN) at different stages of
differentiation shows different recognition patterns
by O-glycan-specific lectins [14], suggesting the ac-
tive participation of O-glycosidically linked struc-
tures in cancer progression. In this work, we ana-
lyzed mucin type O-glycosylation in biopsies of in-
vasive cervical cancer in FIGO stage II B through
histochemistry using lectins specific for O-glycosid-
ically linked glycans.
Mucin-type O-glycosylation is initiated by a large
family of UDP-GalNAc: polypeptide GalNAc-trans-
ferases that adds GalNAc to selected Ser and Thr
residues. Further assembly of O-glycan chains involves
different biosynthetic pathways. The O-glycosidical-
ly linked glycans present in glycoproteins could be
initiated by mucin-type core-1 (Galb1,3GalNac-Ser/
/Thr, or T antigen) or by UDP-GalNAcb1,3Gal-trans-
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Figure 1. Lectin histochemistry of human normal cervical tissues and from patients with cervico-uterine cancer. A. H&E of
cervical tissue from healthy individuals without alterations in either epthelia (dotted arrow Ep) or stroma (dotted arrow St).
B. Healthy cervical tissue showed positive reactivity to PNA in the plasmatic membrane of epithelial cells from the superfi-
cial stratus. C. ALL recognized with moderate capacity the plasmatic membrane from epithelial cells from the superficial
stratus. D. Reactivity to MeA was negative. E. H&E of cervico-uterine cancer tissues depicted loss of epithelial border within
the stroma (dotted arrow T), showing pleomorphic cells and infiltration of the stroma (dotted arrow Sn). F. In cervico-
uterine cancer tissues, PNA showed moderate reactivity to the plasmatic membrane from neoplasic cells that infiltrated the
stroma and the extracellular matrix from the tumoral stroma (solid arrow V). G. ALL showed low to intense reactivity to the
plasmatic membrane of tumoral cells and the extracellular matrix and also to the vascular endothelium and adventitia of
blood vessels (solid arrow V). H. MeA showed positive reaction toward cells and stroma, as well as in the stromal zone.
Biotin labeled lectins were revealed with extravidin-FITC and the nucleus was observed with DAPI staining (blue stain) 40 ×
Figure 2. Specificity of MeA staining for cervico-uterine cancer tissues. A. H&E of cervico-uterine cancer tissues, B. MeA
staining, C. MeA incubated previously with 100 μM porcine stomach mucin oligosaccharides, and D. MeA incubated with
100 mM Gal. Other carbohydrates that showed no effect on MeA interaction were 100 mM Glc, Man, L-Fuc, GalNAc,
and GlcNAc. The carbohydrates were incubated with the lectin for 30 min before histochemistry assays. Nuclei (in blue)
were stained with DAPI (40 ×)
Figure 3. Effect of trypsin treatment on tissues before addition of FITC-labeled MeA. (A) HE-control assays (B) Histo-
chemistry with FITC-labeled MeA; tissues were treated with trypsin for (C) 30, and (D) 120 min before addition of the
MeA lectin. Nuclei (in blue) were stained with DAPI (40 ×)
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ferase activity that could be converted, in turn, to com-
plex-type core-2 by UDP-GlcNAc: Galb1,3GalNAca1,
6GlcNAc-transferase. They could also form mucin-
type core-3 by UDP-GlcNAc:GalNAca1,3GlcNAc-
transferase [25] or more complex structures, such as
core-8 by core-8-a3Gal-transferase [26]. The lectin
PNA showed moderate reactivity to the plasmatic
membrane from neoplasic cells that infiltrated the
stroma. PNA recognizes the hydroxyl group on C-4
of the terminal galactose in the T antigen, as well as
in lactosamine (Galb1,4GlcNAc) residues in N-gly-
cans from glycoproteins or from glycolipids [20, 27].
ALL recognizes GalNAc in the T- or the Tn-antigen
[28]. The lectin ALL showed low to intense reactivity
to the plasmatic membrane of cervical cancer cells
and moderate reactivity toward the extracellular ma-
trix. Expression of the mucin type core-1, identified
by ALL, is highly expressed in CIN II dysplasia com-
pared to CIN I and CIN III or, as shown in this work,
in cervical cancer, suggesting the active participation
of glycosyl-transferases that render complex-type gly-
cosylation during invasiveness [14]. The ability of lec-
tins to bind carbohydrates depends on their 3-D struc-
ture [29, 30] and on their capacity to detect subtle
variations in the conformation of carbohydrate struc-
tures from the cell surfaces [31]. This ability could be
Table 1. Description of lectin reactivity
Lectin labeling of human cervical tissues and cervical cancer
Tissues Lectin
PNA ALL MeA
Normal cervical tissues
Epithelial zones
Superficial + + –
Intermedial – – –
Basal – – –
Stromal zones – – –
Cervical cancer
Epithelioid zones + + + + + +
Stroma zones + + + +
Table 2. MeA WB-bound proteins from cervico-uterine cancer identified in LC Ms/Ms
NCBI Spot* Protein Theoretical Peptides Sequence
Accession No Mass (kDa) matched Coverage**
gi|4503483 4 Elongation factor 2 96 16 25%
gi|119573383 5 Lamin A/C 88 15 23%
gi|11935049 8 Keratin 1  66 4 17%
gi|62414289 9 Vimentin 54 13 64%
gi|4501885528 10 Beta actin 42 6 68%
Only proteins that showed significant ion scores (> 62) are indicated. * MeA positive spot identified in Figure 2A. **Represents the identity with
the indicated protein
5 6 7 pHB
MW
116
97.4
66
45
Figure 4. Ligand blotting assay of cervico-uterine cancer
lysate tissue resolved by 2-D electrophoresis.
(A) Cervico-uterine cancer cell lysate blotted onto
PVDF membrane and stained with Coomassie blue.
(B) Detail of the ligand blotting of cervico-uterine
cancer cells lysate incubated with MeA. Only protein
spots that reacted with MeA consistently over three
experiments are circled. The arrows in panel A indicate
the position of MeA positive spots
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explained by the variability in the size of the carbohy-
drate-recognition domain and the variability in qua-
ternary association [28].
Our results showed that the lectin Machaerocer-
eus eruca showed high capacity to recognize tumoral
cells and tumoral tissue stroma, whereas healthy cer-
vical tissue was negative for MeA. MeA interacts
mainly with the Gal residues present in biantennary
O-glycans possessing the terminal trisaccharide Fuca
1,2 (GalNAca1,3) Galb1,4 in mucin with A+H blood
group determinant [19]. Most of the patterns of pe-
ripheral/terminal glycosylation are polymorphic in
humans and constitute histo-blood groups, among which
we know the systems ABO, secretor, Lewis, T, Tn and P
[8]. These antigen determinants have been identified in
most human epithelia [32] and it has been considered
that H-antigen-related structures confer a highly malig-
nant phenotype and metastatic potential [33, 34].
The lectin MeA showed a higher capacity to spe-
cifically recognize cervical cancer tissues. The fact that
trypsin treatment of tissues abolished the positive rec-
ognition of this lectin suggested that the MeA-recep-
tor seems to be of glycoprotein nature, in contrast to
PNA, which is also able to recognize glycosidically-
linked glycans to lipids [27]; for this reason, further
characterization by Western blot and 2-D electro-
phoresis of MeA-recognized glycoproteins was per-
formed. Our results suggest that, in the cervical can-
cer lysate, MeA recognizes a complex of several gly-
coproteins in the range of 126 to 49 kDa. Nano
LC-ESI-MS/MS analysis identified that the MeA-rec-
ognized glycoproteins with high ion scores corre-
sponded mainly to lamin A/C and to vimentin, and
with lower significance to the elongation factor (EF2),
keratin 1, beta actin, and POTE ankyrin domain fam-
ily member E. Lamin A has been shown to exert
a functional link between the nuclear envelope and
the cell surface functional extracellular matrix in ag-
ing and tumoral processes [35]. Lamin may also af-
fect the extracellular matrix by the closely connected
network of actin-lamin links; this link is affected usu-
ally by oncogenes and may play a role in nuclear en-
velope distortion and in the margin irregularity in tu-
moral processes [36]. Vimentin is a 58-kDa glycopro-
tein that has been considered as a relevant tumor
marker in distinguishing primary endometrial adeno-
carcinomas from endocervical adenocarcinomas [37].
Immunofluorescent stainings of surgical specimens
have indicated that cervical carcinoma progression
and cell invasion is accompanied by vimentin and
epidermal growth factor receptor overexpression [38].
Vimentin is a useful additional diagnostic marker in
the assessment of problematic cervical glandular le-
sions; the expression of vimentin at the deep margin
of some endocervical adenocarcinomas may be rele-
vant to the process of tumor progression and inva-
sion [39, 40]. POTE has recently been found to be
expressed in the majority of ovarian adenocarcinomas
and found at high levels in patients with the worst out-
come [41, 42]. The EF2 showed O-glycosidically linked
glycans containing GlcNAca1,0Ser/Thr and has been
identified in melanoma and gastrointestinal cancers; it
promotes G2/M progression and enhances cell growth
[43, 44]. The beta actin is a 42 kDa protein, and the actin
network seems to play a relevant role in nuclear reorga-
nization in breast cancer cells [45]. The NetOGlyc 3.1
server (www.cbs.dtu.dk/services/netoglyc) was used to
predict the potential of O-glycosylation of the proteins
recognized by MeA [46]. During cancer progression, po-
larized epithelial tumor cells convert into motile mesen-
chymal cells, invade the basement membrane, enter blood
vessels, and disseminate into secondary organs [47]. The
initial stage of these processes is associated with morpho-
logical changes referred to as epithelial-mesenchymal
transition [48]. We suggest the possibility that increased
expression of O-glycosidically-linked proteins, recognized
by the lectin MeA, could result in an upregulation of spe-
cific mucin-type glycosyl-transferases [20, 49], and could
participate in the disassembly of intercellular junctions
as well as in increased cell motility favoring the disrup-
tion of intracellular adhesion junctions and cancer pro-
gression [50–53]. The possibility that MeA receptors rep-
resent an alternative new tool in the diagnosis of cervico-
uterine cancer, or potential biomarkers for cancer risk,
or a target for drug delivery, should not be ruled out.
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